Contrast developer Guerbet is touting the positive results in phase III clinical trials of gadopiclenol, a new MRI gadolinium-based contrast agent for imaging the central nervous system and other areas of the body.
The trials revealed that conducting an MRI scan with gadopiclenol (0.05 mmol/kg) provided comparable results when using gadobutrol at a dose containing twice as much gadolinium (0.1 mmol/kg) to visualize and detect lesions of the central nervous system, as well as in the head and neck, thorax, abdomen, pelvis, and musculoskeletal system.
In the same studies, injecting gadopiclenol during MRI scans also offered superior results at that dose compared with exams completed with no contrast agent, according to the vendor.
In all, 560 patients who were recruited in about 60 hospital medical imaging departments in 13 countries were included in the two trials. Guerbet plans to make regulatory submissions for gadopiclenol in early 2022.
